Stock CLAS.H CLARITAS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Claritas Pharmaceuticals, Inc.

Equities

CLAS.H

CA1806342061

End-of-day quote Toronto S.E.
Other stock markets
 23:00:00 18/07/2022 BST 		5-day change 1st Jan Change
0.025 CAD -16.67% Intraday chart for Claritas Pharmaceuticals, Inc. -.--% -.--%
2021 Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107 MT
2021 Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS
AQ
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
GL
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS
AQ
Claritas Announces Grant of Stock Options to Directors and Officers
GL
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
AQ
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
GL
Claritas Announces Effective Date for Share Consolidation
GL
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation
AQ
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
GL
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
GL
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction
AQ
Claritas Pharmaceuticals Issues Letter to Shareholders
GL
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
GL
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLAS.H Stock
  4. News Claritas Pharmaceuticals, Inc.
  5. Press Releases